A Cardiovascular Risk Calculator for Renal Transplant Recipients.
Soveri I, Holme I, et al.Transplantation, 94(1):57-62, 2012.
Aims
To develop and validate an equation for cardiovascular disease risk prediction in renal transplant recipients.
Interventions
Fluvastatin 40–80 mg daily versus matching placebo. All patients were receiving immunosuppressive therapy with ciclosporin.
Participants
2102 renal transplant recipients with stable graft function who were transplanted at least 6 months before the study.
Outcomes
Major adverse cardiac event and mortality. The variables included in the regression model were: age, previous coronary heart disease, diabetes, low-density lipoprotein, creatinine, number of transplants, and smoking.
Follow-up
Not applicable.
CET Conclusions
Using data from the ALERT trial, major adverse cardiac events could be predicted using a model containing 7 variables. The weakness of the study is that this model has been developed in patients within the ALERT trial and patients were included at least 6 months after transplantation. However it is an interesting model and it would be useful to test the model before and immediately after transplantation.
Data analysis
Strict intention-to-treat analysis
Quality notes
This is a post hoc analysis of a previous publication of the same RCT: Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024–2031. The methodological quality assessment was based on the previous publication.
Trial registration
Not reported